Ixekizumab exposure associated with myelitis: A case report and a literature review

被引：3

作者：

Romozzi, Marina ^{[1
,2
]}

Bellavia, Simone ^{[1
,2
]}

Caldarola, Giacomo ^{[1
,3
]}

De Simone, Clara ^{[1
,3
]}

Luigetti, Marco ^{[1
,2
]}

Calabresi, Paolo ^{[1
,2
]}

Di Filippo, Massimiliano ^{[4
]}

Masullo, Carlo ^{[1
,2
]}

Lucchini, Matteo ^{[1
,2
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Dipartimento Neurosci, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Dipartimento Dermatol, Rome, Italy

[4] Univ Perugia, Clin Neurol, Dipartimento Med & Chirurgia, Osped Santa Maria Misericordia, Perugia, Italy

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2021年 / 361卷

关键词：

Ixekizumab; IL-17; Psoriatic arthritis; Myelitis; CNS inflammation; NEUROLOGICAL ADVERSE EVENTS; ACUTE TRANSVERSE MYELITIS; FACTOR-ALPHA THERAPY; DEMYELINATING DISEASE; ETANERCEPT; PSORIASIS; ANTIBODY; PATIENT; LESIONS; SAFETY;

D O I：

10.1016/j.jneuroim.2021.577726

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe a case of a 28-year-old man who developed a cervical myelitis while exposed to ixekizumab (IL-17 inhibitor) for psoriatic arthritis. Spinal MRI showed a T2 hyperintense lesion at the C4-C5 level while brain MRI was unspecific. Oligoclonal bands were absent and extensive screening for autoimmunity was negative. Rechallenge with ixekizumab was positive corroborating a relation between drug exposure and the neurological event. To the best of our knowledge, this is the first case of CNS inflammatory adverse event associated with ixekizumab. We also provide a review of case reports of demyelinating disorders associated with the use of biologic drugs for the treatment of psoriasis and psoriatic arthritis.

引用

页数：6

共 44 条

[1] Bilateral Optic Neuritis Associated with the Use of Infliximab
Aasly, Jan O.
[J]. CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2011, 2011
[2] Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature
Andreadou, E.
Kemanetzoglou, E.
Brokalaki, Ch.
Evangelopoulos, M. E.
Kilidireas, C.
Rombos, A.
Stamboulis, E.
[J]. CASE REPORTS IN NEUROLOGICAL MEDICINE, 2013, 2013
[3] Demyelination during anti-tumour necrosis factor therapy for psoriasis
Boggs, J. M. E.
Barnes, L.
[J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (05) : 577 - 578
[4] Adalimumab-associated optic neuritis
Chung, Jacob H.
Van Stavern, Gregory P.
Frohman, Larry P.
Turbin, Roger E.
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 244 (1-2) : 133 - 136
[5] Neurological adverse events under anti-TNF alpha therapy
Cohen, M.
Baldin, B.
Thomas, P.
Lebrun, C.
[J]. REVUE NEUROLOGIQUE, 2012, 168 (01) : 33 - 39
[6] Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy
Cortese, Rosa
Prosperini, Luca
Stasolla, Alessandro
Haggiag, Shalom
Villani, Veronica
Simone, Isabella Laura
Gasperini, Claudio
Tortorella, Carla
[J]. JOURNAL OF NEUROLOGY, 2021, 268 (08) : 2895 - 2899
[7] Ixekizumab for the treatment of psoriasis: up-to-date
Craig, Sarah
Warren, Richard B.
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (06) : 549 - 557
[8] Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
Cruz Fernandez-Espartero, Maria
Perez-Zafrilla, Beatriz
Naranjo, Antonio
Esteban, Carmen
Ortiz, Ana M.
Gomez-Reino, Juan J.
Carmona, Loreto
[J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (03) : 524 - 533
[9] Davis SA, 2008, J RHEUMATOL, V35, P1469
[10] A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions
Diebold, Martin
Mueller, Simon
Derfuss, Tobias
Decard, Bernhard F.
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 38 - 40

← 1 2 3 4 5 →